TY - JOUR
KW - COVID-19
KW - Delivery of Health Care, Integrated
KW - Female
KW - Humans
KW - New England
KW - Opioid-Related Disorders/drug therapy/rehabilitation
KW - Postpartum Period
KW - Pregnancy
KW - Prenatal Care
KW - Safety-net Providers
KW - Telemedicine
KW - United States
KW - Substance use treatment
AU - E. W. Patton
AU - K. Saia
AU - M. D. Stein
A1 - 
AB - The COVID-19 pandemic has directly impacted integrated substance use and prenatal care delivery in the United States and has driven a rapid transformation from in-person prenatal care to a hybrid telemedicine care model. Additionally, changes in regulations for take home dosing for methadone treatment for opioid use disorder due to COVID-19 have impacted pregnant and postpartum women. We review the literature on prenatal care models and discuss our experience with integrated substance use and prenatal care delivery during COVID-19 at New England's largest safety net hospital and national leader in substance use care. In our patient-centered medical home for pregnant and postpartum patients with substance use disorder, patients' early responses to these changes have been overwhelmingly positive. Should clinicians continue to use these models, thoughtful planning and further research will be necessary to ensure equitable access to the benefits of telemedicine and take home dosing for all pregnant and postpartum patients with substance use disorder.
AD - Boston University School of Medicine, Department of Obstetrics and Gynecology, 85 East Concord St, 6th Floor, Boston, MA 02118, United States of America; Boston Medical Center, 850 Harrison Ave, Boston, MA 02118, United States of America. Electronic address: Elizabeth.Patton@bmc.org.; Boston University School of Medicine, Department of Obstetrics and Gynecology, 85 East Concord St, 6th Floor, Boston, MA 02118, United States of America; Boston Medical Center, 850 Harrison Ave, Boston, MA 02118, United States of America. Electronic address: Kelley.Saia@bmc.org.; Boston University School of Public Health, Department of Health Law, Policy and Management, 715 Albany St, Talbot Building, Boston, MA 02118, United States of America. Electronic address: mdstein@bu.edu.
BT - Journal of substance abuse treatment
C5 - Healthcare Disparities; Healthcare Policy; HIT & Telehealth; Medical Home; Opioids & Substance Use
DO - 10.1016/j.jsat.2020.108273
JF - Journal of substance abuse treatment
LA - eng
M1 - Journal Article
N2 - The COVID-19 pandemic has directly impacted integrated substance use and prenatal care delivery in the United States and has driven a rapid transformation from in-person prenatal care to a hybrid telemedicine care model. Additionally, changes in regulations for take home dosing for methadone treatment for opioid use disorder due to COVID-19 have impacted pregnant and postpartum women. We review the literature on prenatal care models and discuss our experience with integrated substance use and prenatal care delivery during COVID-19 at New England's largest safety net hospital and national leader in substance use care. In our patient-centered medical home for pregnant and postpartum patients with substance use disorder, patients' early responses to these changes have been overwhelmingly positive. Should clinicians continue to use these models, thoughtful planning and further research will be necessary to ensure equitable access to the benefits of telemedicine and take home dosing for all pregnant and postpartum patients with substance use disorder.
PY - 2021
SN - 1873-6483; 0740-5472; 0740-5472
SP - 108273
T1 - Integrated substance use and prenatal care delivery in the era of COVID-19
T2 - Journal of substance abuse treatment
TI - Integrated substance use and prenatal care delivery in the era of COVID-19
U1 - Healthcare Disparities; Healthcare Policy; HIT & Telehealth; Medical Home; Opioids & Substance Use
U2 - 33771277
U3 - 10.1016/j.jsat.2020.108273
VL - 124
VO - 1873-6483; 0740-5472; 0740-5472
Y1 - 2021
Y2 - May
ER -